AXA Framlington Biotech

AXA Framlington Biotech Z Acc

  • FE Crown Rating: 2
  • FE Manager Rating:
  • Trustnet Direct 100:
    1year Growth
AXA Framlington Biotech Z Acc 17.7%
Specialist
12.4%
  (Benchmark)  
0 150+
220
83

FE RISK SCORE

 
1year
3year
1st Quartile
 
 
2nd Quartile
 
 
3rd Quartile
 
 
4th Quartile
 
 

FUND RANKING

Currency: GBX
Mid: 327.20
Change: -4.00
Yield: n/a

PRICE

Initial Charges: 0.00%
Annual Mgt. Charge: 0.75%
Ongoing Charges Figure: 0.82%
ISA: SIPP:

CHARGES

Advertisement

2a
PAST PERFORMANCE: FUND VS SECTOR
1b
FUND MANAGER CLOSE
    Linden Thomson 05-Jul-2012 to Present
    Manager Picture

    Linden Thomson

    +21.1%

    Fund annualised total return over 5.1 years

    Manager Picture

    Gemma Game

    +30.0%

    Fund annualised total return over 1.3 years

    Manager Picture

    Deane Donnigan

    -0.9%

    Fund annualised total return over 0.7 years

    Manager Picture

    Andy Smith

    +14.9%

    Fund annualised total return over 2.2 years

    Manager Picture

    Deane Donnigan

    -12.5%

    Fund annualised total return over 0.6 years

    Linden Thomson joined AXA IM in June 2011 as sector specialist on the Healthcare equity desk. Linden joined AXA IM from Hedge Fund Clear River Capital where she was responsible for fundamental stock research acr...

    Gemma joined AXA Framlington in October 2007 as a Senior Portfolio Manager. Prior to this Gemma was a vice president at BlackRock, where she was a portfolio manager on the Global Equities Team covering the healt...

    Deane joined AXA Framlington in October 1997. She currently manages the AXA Framlington Health Fund and AXA Framlington Biotech Fund. Deane attended University of Georgia and the Medical College of Georgia, spen...

    FULL DETAILS
  • +21.1%

    Fund annualised total return over 5.1 years

    Linden Thomson - Primary Manager Managed this fund 05-Jul-2012 to Present

    +30.0%

    Fund annualised total return over 1.3 years

    Gemma Game Managed this fund 01-Mar-2011 to 04-Jul-2012

    -0.9%

    Fund annualised total return over 0.7 years

    Deane Donnigan Managed this fund 18-Jun-2010 to 28-Feb-2011

    +14.9%

    Fund annualised total return over 2.2 years

    Andy Smith Managed this fund 01-Apr-2008 to 17-Jun-2010

    -12.5%

    Fund annualised total return over 0.6 years

    Deane Donnigan Managed this fund 01-Sep-2007 to 31-Mar-2008

    +1.4%

    Fund annualised total return over 3.7 years

    Gareth Powell Managed this fund 01-Jan-2004 to 31-Aug-2007

    -12.0%

    Fund annualised total return over 3.3 years

    Antony Milford Managed this fund 26-Nov-2001 to 28-Feb-2005
SUMMARY DETAILS
 
4d
FUND OBJECTIVES & COMPANY INFO
The aim of this Fund is to provide long-term capital growth.
Investment Objectives
The aim of this Fund is to provide long-term capital growth.

Contact Details
7 Newgate Street, London, EC1A 7NX
0845 766 0184 (Broker Line)
0844 620 0151 (Fax Number)
0845 777 5511 (Main Number)


broker.services@axa-im.com
MORE & FULL COMPANY INFORMATION
5e
PORTFOLIO BREAKDOWN & HISTORY
  Name Total% Rank (Prev)
 
BIOGEN INC
9.53 1 2
 
GILEAD SCIENCES INC
8.98 2 1
 
CELGENE CORP
8.12 3 4
  Name Total% Rank (Prev)
 
Biotechnology/Medica...
78.62 1 1
 
Pharmaceuticals
14.62 2 2
 
Electronic & Electri...
2.79 3 5
 NameTotal%Rank(Prev)
 
US Equities
85.21 1 1
 
UK Equities
3.84 2 2
 
French Equities
3.20 3 3
Estimated from fund's sector average
 NameTotal%Rank(Prev)
 
USA
85.21 1 1
 
UK
3.84 2 2
 
France
3.20 3 3
Top 10 Holdings
 NameTotal%Rank(Prev)
 
BIOGEN INC
9.53 1 2
 
GILEAD SCIENCES INC
8.98 2 1
 
CELGENE CORP
8.12 3 4
 
REGENERON PHARMACEUT...
7.50 4 3
 
ALEXION PHARMACEUTIC...
5.70 5 6
 
AMGEN INC
4.78 6 5
 
BIOMARIN PHARMACEUTI...
3.65 7 -
 
INCYTE CORP
3.36 8 8
 
VERTEX PHARMACEUTICA...
3.09 9 -
 
OXFORD IMMUNOTEC GLO...
2.17 10 -
TOTAL56.88  
Top 10 Sectors
 SectorTotal%Rank(Prev)
 
Biotechnology/Medica...
78.62 1 1
 
Pharmaceuticals
14.62 2 2
 
Electronic & Electri...
2.79 3 5
 
Technology
1.89 4 4
 
Money Market
1.12 5 3
 
Health Care
0.96 6 6
    
    
    
    
TOTAL100.00  
Top 10 Assets
 AssetTotal%Rank(Prev)
 
US Equities
85.211 1
 
UK Equities
3.842 2
 
French Equities
3.203 3
 
Belgian Equities
3.094 5
 
Swedish Equities
2.645 4
 
Money Market
1.126 6
 
German Equities
0.427 8
 
Canadian Equities
0.418 9
 
Swiss Equities
0.079 7
    
TOTAL100.00  
Estimated from fund's sector average
Top 10 Regions
 RegionsTotal%Rank(Prev)
 
USA
85.211 1
 
UK
3.842 2
 
France
3.203 3
 
Belgium
3.094 5
 
Sweden
2.645 4
 
Money Market
1.126 6
 
Germany
0.427 8
 
Canada
0.418 9
 
Switzerland
0.079 7
    
TOTAL100.00  
SHOW ALL
7f 5e
KEY STATISTICS
Fund Type: United Kingdom UK Unit Trust Minimum Investment: £100
Launched: 16-Apr-2012 Minimum Regular Investment: £20
Fund size: £543.6m / $708.8m (25-Jul-17) Dealing Charge: £10 or £6 for frequent traders
Dealing Frequency: Daily Initial Charge: 0.00%
Dealing Time: 9.00 A.M. 5.30 P.M. Annual management charge: 0.75%
Price Times: 12:00 Daily Note to charges: n/a
Fund Type: United Kingdom UK Unit Trust
Launched: 16-Apr-2012
Fund size: £543.6m / $708.8m (25-Jul-17)
Dealing Frequency: Daily
Dealing Time: 9.00 A.M. 5.30 P.M.
Price Times: 12:00 Daily
Trustee / Depositary: National Westminster Bank plc
Registrar: IFDS
Minimum Investment: £100
Minimum Regular Investment: £20
Dealing Charge £10 or £6 for frequent traders ?
Initial Charge: 0.00%
Annual management charge: 0.75%
Note to charges: n/a
Dividend Policy: Mar 01, Sep 01 (Final)
Multi-manager: n/a
Index: Nasdaq Biotechnology
ISA: ISA Wrapper
Savings plan: Savings Plan
CAT Standard: CAT Standard
ISIN: GB00B784NS11
Sedol: B784NS1
SHOW ALL
8g
RATIOS
1year 3year
Volatility 20.04 24.44
Alpha 27.53 12.80
Beta 0.10 0.78
Sharpe 1.18 0.50
InfoRatio 0.50 0.35
RSquared 0.00 0.10
QUARTILES KEY:
1st 2nd 3rd 4th

Fund Filter

Find the best,
fast, from our
huge fund range.

JUST A FEW CLICKS

Trustnet Direct
Top 100 Funds

THE TRUSTNET DIRECT 100

5 big reasons
to open an
account

#5
Straightforward
low charges, that
stay low.

FIND OUT MORE

SIPP: Self Invested Personal Pension

Get a clear view
of the advantages

A GIFT FROM THE GOVERNMENT
 
CLOSE